The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy

Exp Nephrol. 2002;10(3):227-34. doi: 10.1159/000058349.

Abstract

Renal cell carcinoma tumor cells are intrinsically resistant to chemotherapy, but unlike most solid tumors, may be susceptible to immune-based therapy. Because powerful immune effects can be generated against hematological malignancies following allogeneic stem cell transplantation, we investigated for similar anti-tumor responses in patients with metastatic renal cell carcinoma following the transplantation of an allogeneic immune system from a healthy HLA-matched family donor. Early laboratory and clinical results have demonstrated that following a reduced-intensity allogeneic stem cell transplant, donor T-cell mediated anti-tumor effects, resulting in sustained and sometimes complete tumor regression, can be generated against renal cell carcinoma (RCC) refractory to conventional cytokine-based therapy. Early data indicate that cytotoxic T cells of donor origin are the mediators of these anti-tumor effects. These preliminary studies provide additional evidence supporting the susceptibility of RCC to immune attack and lay the foundation for future targeted allo-immune-based cancer strategies.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / therapy*
  • Cohort Studies
  • Graft vs Tumor Effect
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Immunotherapy, Adoptive / methods*
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / therapy*
  • Models, Immunological
  • Sensitivity and Specificity
  • Stem Cell Transplantation / adverse effects
  • Stem Cell Transplantation / methods*
  • Transplantation, Homologous
  • Treatment Outcome